Nurix Therapeutics annual meeting: stockholders elect directors, ratify auditor, approve say-on-pay

Nurix Therapeutics, Inc.

Stockholders elected directors Julia P. Gregory (29.9M for, 4.5M withheld) and David L. Lacey (27.1M for, 7.3M withheld) to terms expiring 2027.
Ratified PricewaterhouseCoopers LLP as independent auditor for FY ending Nov 30, 2024 (39.0M for, 16.7K against).
Non-binding advisory vote on named executive officer compensation passed: 30.4M for, 4.0M against, 77.4K abstentions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.